Jump to main content

The New York Times 10/12/2016

Drug Coupons: Helping a Few at the Expense of Everyone

Margot Sanger-Katz reports on the negative effects of drug coupons, citing a paper written by Dr. Peter Ubel and Dr. Peter Bach that outlines the issue and prescribes policy solutions.

“When a furor erupted over the rapidly rising price of EpiPens this summer, the drugmaker Mylan offered a solution: a coupon for the expensive drug.

People who need the EpiPens to protect themselves from life-threatening allergic reactions could use the coupon to get up to $300 off at the pharmacy counter if their insurance plan has a deductible or a co-payment…”

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Explore Our Research

Copay Assistance: The Epipen Example

What happens when a patient uses a copay coupon?

Drug Pricing Lab 06/06/2017

Academic Literature

Copay Assistance for Expensive Drugs: A Helping Hand That Raises…

Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.

Annals of Internal Medicine 12/20/2016

Xeljanz, the FDA, and nine years of patient harm

Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action

Drug Pricing Lab 05/31/2022

Atypical antipsychotics: Decades of use, unfathomable harms

Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly

Drug Pricing Lab 05/31/2022

Medicare Part B Premium Dynamics Explained

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Milliman 12/23/2021

Comparing Factors that Influence Pharmaceutical Pricing and Access in the…

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

Drug Pricing Lab 12/20/2021

Biosimilars in Medicare Part D: pricing dynamics and considerations

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

Milliman 12/14/2021

Evaluating Industry’s Drug Pricing Claims

A closer look at three of PhRMA’s most cited talking points.

Drug Pricing Lab 11/18/2021

Mapping conflict of interests: scoping review

A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.

Drug Pricing Lab 11/03/2021

Production Plus Profit Pricing (P-quad) FAQ

Academic Literature

What A Waste! The National Academy Of Medicine’s Report On…

Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.

Health Affairs Blog 07/09/2021

Medicare Must Study Unproven, Expensive Alzheimer’s Drug

Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.

Bloomberg Opinion 06/15/2021

Explore Our Research